Summary
- Profile Type
- Technology offer
- POD Reference
- TORO20240410015
- Term of Validity
- 10 April 2024 - 10 April 2025
- Company's Country
- Romania
- Type of partnership
- Research and development cooperation agreementInvestment agreementCommercial agreement with technical assistance
- Targeted Countries
- CanadaCyprusBelgiumAustriaCzechiaItalyHong KongFranceEstoniaGermanyMaltaLatviaDenmarkIrelandFinlandLithuaniaLiechtensteinGreeceLuxembourgSpainSlovakiaAndorraSwedenUnited KingdomNorwayPolandAustraliaMonacoSwitzerlandPortugalNetherlandsUnited StatesSlovenia
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The Romanian company develops a medical device based on Artificial Intelligence applied in the field of Endoscopic Ultrasound. They are interested in signing technical cooperation agreements with foreign partners, regardless of their country of origin.
- Full Description
-
The 2022 founded Romanian start-up specialises in the development of a novel, AI-assisted device intended to aid endoscopists in the real-time detection and identification of pancreatic structures during endoscopic ultrasound (EUS) of the pancreas.
The company was founded with a clear mission in mind: to revolutionise the field of healthcare diagnostics, particularly in the context of pancreatic cancer detection. Their journey began with a start-up grant received from Orlando Health Hospital, Florida, USA that brought together experts from various domains, including AI, medical research, and software development.
During the prototype development phase, they developed advanced software aimed at improving the precision and efficiency of pancreatic tumours and cysts detection during endoscopic ultrasound. This cutting-edge technology was refined through rigorous testing in the hospital, and collaboration with medical professionals, leading to the creation of a prototype that showcased its potential to significantly impact the healthcare industry.
As they progressed, they recognised the pressing need for accurate and minimally invasive diagnostics in pancreatic cancer, a disease with far-reaching implications for patients and healthcare systems worldwide. This realisation fueled the company’s determination to transform their prototype into a market-ready solution that could benefit patients, healthcare providers, and society at large.
A first generation of the Panc AI software is implemented at Orlando Health for clinical evaluation to identify suspicious structures in EUS images of the pancreas under an IRB protocol approved by OH. The company would like to partner up internationally and especially in the EU under technical cooperation agreements. They seek hospital and medical clinic partners specialising in liver and pancreatic pathologies to collaborate on a prospective, multi-center, investigator-randomised observational validation clinical reader study for their application. By means of undertaking the afore-mentioned cooperation endeavours, they aim to further develop their application and perfect it for market introduction. - Advantages and Innovations
-
The Romanian company aims setting new standards for the diagnosis and treatment of pancreatic cancer and other critical medical conditions. They envision a future where their AI powered medical imaging analysis system is widely adopted, reducing the burden of late-stage cancer diagnoses, improving patient outcomes, and ultimately saving lives.
Their vision encompasses:
- they aim to continuously advance the precision and capabilities of our technology through research and development, staying ahead of the curve in medical diagnostics.
- they aspire to make their technology accessible on a global scale, ensuring that accurate and minimally invasive diagnostics are available to all, regardless of geographic location.
- they are dedicated to conducting their operations with environmental responsibility, contributing to a greener and more sustainable future.
The company ambitiously roots its dedication to innovation, healthcare excellence and positive societal impact. They aspire to:
- Commercialise Their Innovation: they are committed to bringing their AI medical system to market, obtaining regulatory approvals, and making it accessible to healthcare providers worldwide.
- Improve Patient Outcomes: their ambition is to contribute to earlier diagnosis, better treatment outcomes and higher survival rates for patients facing pancreatic cancer and other life-threatening conditions.
- Foster Collaborations: they aim to strengthen collaborations with partners, institutions and organisations that share their commitment to healthcare innovation, ensuring their impact reaches even further.
- Expand their Reach: they plan to expand their product portfolio to address additional healthcare challenges, leveraging their expertise in AI, software, and medical technology.
- Lead in Ethical Practices: they are determined to uphold the highest ethical standards in healthcare and technology, setting an example for responsible innovation and corporate citizenship. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR description
- They are currently seeking hospital and medical clinic partners specialising in pancreatic pathologies to collaborate on a prospective, multi-center, investigator-randomised observational validation clinical reader study for their application. This study aims to validate the app by evaluating its performance during endoscopic ultrasound (EUS) of the pancreas in detecting and delineating pancreatic structures, including the pancreas itself, cystic pancreatic lesions and solid pancreatic masses/tumours, and comparing it to standard EUS procedures. The study plans to involve a participant sample size ranging from 100 to 200 patients, with the exact number to be determined in the statistical analysis plan. Adult patients referred for pancreatic EUS will undergo sequential EUS procedures, one utilising the application and one without, both conducted during the same session. Fine needle aspiration/ biopsy (FNA/FNB) and pathology will be performed according to the standard of care for lesion identification.
Partner Sought
- Expected Role of a Partner
- The company is interested in signing technical cooperation agreements with hospital and medical clinic partners from abroad. Sought partners should specialise in pancreatic pathologies. Cooperation projects are sought on the axis of prospective, multi-center, investigator-randomised observational validation clinical reader studies. They are currently seeking hospital and medical clinic partners specialising in pancreatic pathologies to collaborate on a prospective, multi-center, investigator-randomised observational validation clinical reader study for their application. This study aims to validate the app by evaluating its performance during endoscopic ultrasound (EUS) of the pancreas in detecting and delineating pancreatic structures, including the pancreas itself, cystic pancreatic lesions and solid pancreatic masses/tumours, and comparing it to standard EUS procedures. The study plans to involve a participant sample size ranging from 100 to 200 patients, with the exact number to be determined in the statistical analysis plan. Adult patients referred for pancreatic EUS will undergo sequential EUS procedures, one utilising the application and one without, both conducted during the same session. Fine needle aspiration/ biopsy (FNA/FNB) and pathology will be performed according to the standard of care for lesion identification.
- Type and Size of Partner
- SME 11-49R&D InstitutionSME 50 - 249SME <=10Big companyUniversity
- Type of partnership
- Research and development cooperation agreementInvestment agreementCommercial agreement with technical assistance
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis06001002 - Clinical Research, Trials06001012 - Medical Research01004001 - Applications for Health
- Market keywords
- 05001001 - Diagnostic services05002003 - Ultrasound imaging05003001 - Therapeutic services05004004 - Medical instruments
- Targeted countries
- CanadaCyprusBelgiumAustriaCzechiaItalyHong KongFranceEstoniaGermanyMaltaLatviaDenmarkIrelandFinlandLithuaniaLiechtensteinGreeceLuxembourgSpainSlovakiaAndorraSwedenUnited KingdomNorwayPolandAustraliaMonacoSwitzerlandPortugalNetherlandsUnited StatesSlovenia